Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated June 2, 2025, reports a transaction in the company's own shares. The filing covers a specific share repurchase executed on May 30, 2025, as part of an ongoing buyback program.
Key Financial Metrics and Transaction Details
- Shares Purchased: 528,198 ordinary shares.
- Price Range: Lowest price paid was 1,459.00 GBp; highest price paid was 1,516.50 GBp.
- Average Price: Volume-weighted average price paid was 1,488.59 GBp.
- Trading Venue: All transactions occurred on the London Stock Exchange (XLON).
- Treasury Holdings: Following this purchase, GSK holds 217,152,078 ordinary shares in treasury.
- Shares in Issue: 4,098,115,196 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.30% of total voting rights.
Material Changes and Program Progress
This transaction is part of a non-discretionary agreement with Citigroup Global Markets Limited entered into on February 24, 2025. Since the inception of this specific agreement, the company has purchased a total of 48,081,775 ordinary shares. The filing does not provide comparative financial data (revenue, profit, or cash flow) as it is a disclosure of a capital transaction rather than a periodic financial report.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that actual results may differ materially from projections due to risks and uncertainties, referencing the "Risk Factors" section in its 2024 Annual Report on Form 20-F and its Q1 2025 Results. No new specific guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback program initiated on February 24, 2025.
- Confirm the impact of the 5.30% treasury share holding on earnings per share (EPS) calculations.
- Review the Q1 2025 Results and 2024 Form 20-F for the full context of risk factors mentioned in the cautionary statement.
- Monitor subsequent 6-K filings to track the completion status of the non-discretionary buyback agreement.